Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Boston Scientific ( (BSX) ) just unveiled an announcement.
Boston Scientific Corporation has announced the resumption of its AVANT GUARD clinical trial, focusing on drug-naïve patients with persistent atrial fibrillation. This decision follows a thorough assessment and collaboration with the study’s data monitoring committee, signaling potential advancements in treatment options for this patient group.
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.
